Study details
Enrolling now
Belimumab Trial for Early Lupus
Northwell Health
NCT IDNCT03543839ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
30
Study length
about 6.3 years
Ages
18+
Locations
1 site in NY
What this study is about
Researchers are testing belimumab, a medication, in people with early lupus. Participants will receive either belimumab or a placebo for two years. The trial will examine the effects of belimumab on clinical symptoms and immune markers.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Receive Belimumab
- 3.Receive Belimumab/Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IV
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
belimumab
Drug routes
injection (Injection)
Endpoints
Secondary: Safety and tolerability (adverse events)
Body systems
Immune